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Brown Medical School

Hepatitis B Virus: Transmission, Prevention,
Treatment and HIV Co-Infection
David Paar, M.D.*, Associate Professor of Medicine, Director, HIV Care/TDCJ Correctional Managed Care

Hepatitis B Virus (HBV) infection is very common with over
350 million chronically infected
people worldwide including 1.25
million in the United States. The
incidence of acute HBV infection in the U.S. has declined
from 450,000 new infections per
year in the 1980s to 80,000 in
1999. Vaccination against HBV,
which has been available since
1982, is primarily responsible
for this decline. Twenty to 80 %
of U. S. inmates have past or
active HBV infection, and 0.8 
1.4 % of inmates acquire HBV
while in prison (1, 2, 3).
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HBV TRANSMISSION

High rates of HBV infection occur in people who have multiple sex partners, people who have percutaneous blood exposures (those who share injecting drug equipment and patients on hemodialysis) and health care or public safety workers who have frequent exposure to contaminated blood or
other infectious fluids. In the correctional environment, tattooing with contaminated needles may be
associated with HBV acquisition. Correctional officers may also be at increased risk of HBV infection
because of exposure to inmates blood and other body fluids during the course of their work.
Household contacts of those with acute or chronic HBV infection and infants of mothers with chronic HBV infection are also at risk for acquiring HBV. In prisons, cellmates are analogous to household
contacts. Transfusion as a cause of acute Hepatitis B (and Hepatitis C) has decreased dramatically
in the past two decades since screening has become increasingly sensitive and more cost-effective.
Since HIV and HBV have similar modes of transmission, coinfection is quite common.

ACUTE HEPATITIS B INFECTION

The clinical, serologic, and immunologic responses following infection with HBV infection have been
well-described. Only 25 - 50 % of cases of acute HBV infection are symptomatic; the remainder are
asymptomatic or are associated with inconsequential symptoms. Following an incubation period that
varies from one week to six months, symptoms of the pre-icteric phase include malaise, weakness,
anorexia, nausea, vomiting, and right upper quadrant pain. Oddly, these symptoms begin to abate
during the icteric phase (jaundice) that persists for approximately three weeks. The hepatic transaminases peak, and then begin to decline during this time period. During the convalescent phase, which
may last for up to six months, symptoms completely resolve (4).
Following exposure to HBV, a well-defined immunologic response results in resolution of infection
and protective immunity. The first serologic marker of HBV infection to appear is Hepatitis B surface
antigen (HBsAg), a protein on the surface of the
virus. This antigen usually persists in serum
throughout the period of clinical illness, and is
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acute HBV infection, resolution occurs in
six months or less. In addition, there are
other serologic and immunologic markers
of acute HBV infection. Hepatitis B core
antibody (anti-HBc), an antibody directed
against the nucleocapsid of HBV generally
appears at approximately the same time as
HBsAb. HBc IgM develops initially and is
eventually replaced by HBc IgG. In the
minority of cases of acute HBV infection
that come to clinical attention, HBsAb
develops prior to the icteric phase. Since
HBsAg disappears when HBsAb develops,
HBsAg cannot be used to make the diagnosis of acute HBV infection in these rare
instances. Instead, HBc IgM must be used
to confirm the diagnosis. Another viral protein, Hepatitis B e antigen (HBeAg) and its
corresponding antibody (HBeAb) follow a
similar course to HBsAg and HBsAb, but
these markers are rarely used for diagnosis
of acute HBV infections. Seroconversion of
HBeAg to HBeAb is associated with a
decline in viral replication and disease
severity (4). Figure 1 summarizes the serologic and immunologic responses encountered in acute HBV infection.

CHRONIC HBV INFECTION

In approximately 10 % of new infections,
HBsAg persists in the serum for greater
than six months, and chronic HBV infection
is established. Individuals with persistent
HBsAg are often called chronic carriers.
Prior infection with HIV increases the likelihood that chronic HBV infection will occur.
The course of chronic HBV infection is
characterized by the persistence of HbsAg
in the serum and the failure to develop
HBsAb, which provides protective immunity. In chronic HBV infection, the persistence
of HBeAg (and failure to develop HBeAb) is
associated with greater viral replication,
higher HBV DNA in the serum, and more
severe disease.
In the liver, chronic HBV infection causes
inflammation, hepatic cell necrosis, and cirrhosis in approximately 50% of those
infected. Hepatic failure and/or hepatocellular carcinoma occur in a significant number of patients. Chronic HBV infection is
characterized by periods of disease activity
and periods of disease quiesence. Serum
transaminase levels increase with
increased disease activity and may
decrease to within normal limits during periods of disease quiesence. Serum quantitative HBV DNA levels also vary with disease
activity. Clinically, symptoms may wax and
wane with disease activity and may include
fatigue, right upper quadrant discomfort,
jaundice, and mild fever. Some patients
are asymptomatic (4). Figure 2 summarizes the serologic and immunologic course
of chronic HBV infection.
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Figure 2. Progression to Chronic Hepatitis B Virus Infection
Acute
(6 months)

Chronic
(Years)

HBeAg

anti-HBe

HBsAg
Total anti-HBc

Titer

lg M anti-HBc

0 4 8 12 16 20 24 28 32 36
Weeks After Exposure

52

Years

Figure 3. Guide to postexposure immunoprophylaxis with HBIG and HBV Vaccine
Type of Exposure

Post Exposure Prophylaxis

Perinatal
Sexual  acute infection
Sexual  chronic carrier
Household contact  chronic carrier
Household contact  acute case
Household contact  acute case,
known exposure
Infant (< 12 months)  acute case in
primary caregiver
Inadvertant percutaneous/permucosal

Vaccination + HBIG
HBIG +/- vaccination
Vaccination
Vaccination
None unless known exposure
HBIG +/- vaccine

TREATMENT OF HBV
INFECTION

There is no specific therapy for acute viral
hepatitis. Supportive therapy including
intravenous fluids, antiemetics, mild analgesia, and antipyretics may be necessary
in some cases. It is prudent to stop potentially hepatotoxic medications, including
antiretroviral drugs, until transaminase levels approach normal values. Acute fulminant hepatitis and death occur in 0.5  1 %
of cases of acute HBV infection.
Treatment and monitoring of patients with
chronic HBV infection should be carried out
by providers who are experienced in managing chronic HBV. Prior to treatment, liver
biopsy is generally performed. Patients
with decompensated liver failure or severe
cirrhosis should not be treated for chronic
HBV infection because treatment in these
cases may actually lead to hepatic failure.
Side effects are commonly encountered
during treatment.
Interferon alpha 2b was the first drug
approved by the United States Food and
Drug Administration (U.S.F.D.A.) for the
treatment of chronic HBV infection. The
recommended treatment course is 5 million
units injected subcutaneously daily or 10
million units injected subcutaneously three
times per week for 16 weeks.
Approximately 40 % of those receiving this
treatment will have a successful outcome,
which is defined as seroconversion of

HBIG + vaccination
Vaccination +/- HBIG

HBeAg (i.e., loss of e antigen and acquisition of HBeAb). It appears that treatment
with interferon reduces the occurrence of
cirrhosis, hepatic failure, and hepatocellular
carcinoma. Co-infection with HIV is a predictor of poor response to interferon treatment.
Lamivudine (Epivir-HBV tablets or oral
solution) has also been approved by the
U.S.F.D.A. for the treatment of chronic HBV
infection. The recommended dosage is 100
mg qd. The optimal duration of treatment is
unclear, although most studies have
involved one year of treatment.
Approximately 15 % of patients treated with
lamivudine have seroconversion of HBeAg.
HBV DNA disappears during treatment, but
usually becomes detectable again when
treatment is stopped. ALT also decreases
during treatment, but may rebound to two
or three times the baseline value after treatment is stopped. Lamivudine-resistant HBV
have emerged during treatment with
lamivudine. It is unclear whether patients
have a decrease in clinical endpoints such
as cirrhosis, liver failure, and hepatocellular
carcinoma following treatment with lamivudine.
Hepatic transplantation is an option for
patients with end-stage liver disease secondary to chronic HBV infection.
Continued on page 4
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Letter from the Editor
Dear Colleagues,
As this edition of HEPP News went to press, we were encouraged by the news that the United
Nations General Assembly has adopted a "Declaration of Commitment on HIV/AIDS". Although
significant concessions were made in the drafting of this document, this does mark the first time
that the General Assembly has convened solely to confront an infectious disease. This declaration sets (non-binding) time frames within which member nations are to expand access to HIV
testing, prevention tools such as male and female condoms, disposable syringes, prenatal care,
and perinatal measures to decrease vertical transmission of HIV. In addition, the declaration calls
for the development of improved health care delivery systems, access to reduced cost medications, measures to promote gender equality and to protect those living with HIV/AIDS, and funding for low and middle income countries to accomplish these goals.
Although we are now twenty years into the HIV epidemic, it is hoped that the increased spotlight
on this issue brought about by the United Nations declaration will mark a turning point in the fight
against AIDS and help to control the explosive growth of HIV worldwide.
In this issue, HEPP News senior advisor David Paar focuses on the diagnosis, treatment, and
prevention of Hepatitis B. By vaccinating our patients and colleagues, we in correctional health
have the opportunity to prevent cancer, cirrhosis, and further transmission of this potentially devastating virus. Dr. Paar also provides an update on the Texas Department of Corrections four
years of experience with telemedicine. This months HEPPigram provides an algorithm for the
management of abnormal liver function tests, while Dr. Nick Capozzoli draws upon his experience
as a correctional neurologist to review peripheral neuropathy.
After reviewing this issue, readers should know more about the management of Hepatitis B, be
able to discuss the use of telemedicine in the delivery of HIV care within corrections, and have a
better understanding of the diagnosis and management of peripheral neuropathy.
This month, we welcome Rebecca Nerenberg as the new managing editor for HEPP News. As
always, we encourage your suggestions for future HEPP News topics!

The editorial board and contributors to HEPP
News include national and regional correctional
professionals, selected on the basis of their
experience with HIV care in the correctional
setting and their familiarity with current HIV
treatment. We encourage submissions, feedback, and correspondence from our readership.
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PREVENTING HBV INFECTION

Avoiding contact with contaminated blood by
using universal precautions is the only way
to be 100% protected against HBV infection.
However, it has been shown that immunization with recombinant HBV vaccine is an
effective means of preventing infection. The
Immunization Practices Advisory Committee
(ACIP) of the Centers for Disease Control
and Prevention recommends that all newborns, children, and adolescents be immunized to help eliminate HBV in the United
States. Adults in high risk groups should be
vaccinated but vaccination of all adults is not
recommended at this time. In addition, older
adults are at lower risk. One hundred ten
other countries have a similar policy.
When vaccination is required, Recombivax
HB and Engerix-B are two preparations that
are available in the United States. The most
common vaccination schedule is three intramuscular injections with the second and third
doses being administered one and six
months after the first; Engerix-B has also
been licensed for a series of four injections
given at 0, 1, 2, and 12 months (2).
When an exposure to HBV occurs in a susceptible individual, postexposure prophylaxis
with Hepatitis B Immune Globulin (HBIG)
and/or vaccination is recommended in most
cases. Figure 3 is a guide to postexposure
prophylaxis (2). Available Hepatitis vaccines
are presented in figure 4.

HBV AND HIV COINFECTION

HIV and HBV interact when they occur in the
same host, as previously noted (5,6). Like
any other infection that occurs in HIV positive
individuals, HBV infection activates the
immune system leading to proliferation of
CD4 cells which enhances HIV replication
and increased plasma HIV RNA (viral load).
In addition to this indirect effect on HIV replication, HBV proteins directly stimulate HIV
replication. Theoretically, this results in more
rapid HIV disease progression if the increase
in HIV replication is sustained for a significant length of time. However, the literature
does not consistently support the presumption that HIV progression is accelerated by
concomitant HBV infection. It does appear

visit HEPP News online at www.hivcorrections.org
Figure 4. Hepatitis Vaccines
Hepatitis A (HAV) Vaccines

Hepatitis B (HBV) Vaccines

G Two HAV vaccines available perform
equally well; both are based on an
inactivated virus
G Two doses are recommended, the second dose given 6-12 months after the first
G Havrix: manufactured by Glaxo Smith
Kline
G VAQTA: manufactured by Merck, there
is a pediatric version available for use
up to 18 years of age
G Twinrix: a combination HAV and HBV
vaccine consisting of inactivated HAV
and genetically derived HBsAg is
currently undergoing trials

G There are three HBV vaccines available;
all are recombinant (genetically
engineered) HBsAg vaccines
G The vaccine schedule involves three
intramuscular injections at 0, 1, and
6 months.
G Engerix-B: manufactured by Glaxo Smith
Kline
G Recombivax-HB: manufactured by Merck
G Comvax: manufactued by Merck,
combination Haemophilus B conjugate
and HBV vaccine

http://www.who.int/vaccines/intermediate/hepatitisa.htm
http://www.cdc.gov/ncidod/diseases/hepatitis/a/index.htm
http://www.who.int/vaccines/intermediate/hepatitisb.htm

however that HIV infection may accelerate
the progression to hepatic failure and hepatic failure-related deaths in patients with
chronic HBV infection (6).
In coinfected patients, most published
reports indicate that serum HBV DNA is higher, serum alanine aminotransferase levels
(ALT) are lower, and liver inflammation and
cirrhosis are less than in patients with HBV
alone. This is not an unexpected finding
since cell-mediated-immunity (CMI), the primary factor in eliminating HBV from infected
hepatocytes, is impaired by HIV infection. In
studies that demonstrated the efficacy of
interferon-alpha 2b for chronic HBV infection,
HIV negative participants with high serum
HBV levels, low serum ALT levels, and mild
histopathologic scores on liver biopsy were
less likely to respond to interferon treatment
for chronic HBV infection than participants
who had lower HBV DNA levels, higher ALT
levels, and more severe inflammation on
liver biopsy. Given this fact, it is not surprising that patients with chronic HBV and HIV
coinfection are less likely to respond to
interferon treatment for chronic HBV infection. Patients with chronic HBV and HIV are
more likely to have clinically significant
hepatotoxicity when placed on antiretroviral
agents in general and may have increased
incidence and severity of indinavirassociated hyperbilirubinemia (7).

*Speakers Bureau: Roche Pharmaceuticals
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CORRECTIONAL HEPATITIS
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Telemedicine in Clinical Practice

An Update From The Texas Department of Criminal Justice (TDCJ)
by David Paar, Associate Professor of Medicine, Director, HIV Care/TDCJ Correctional Managed Care
Telemedicine was introduced in the U.S. in the late 1950s using the
limited technology of the time, and despite enormous technological
advances that have made remote real-time audiovisual communication, examination, and robotically controlled surgical procedures
possible, the practical application of telemedicine remains limited.
Provider acceptance remains a significant factor in the limited use of
telemedicine, which is a particular concern for HIV-treating physicians since a satisfactory/trusting patient/provider relationship has
been identified as one of the most significant factors in predicting
adherence to antiretroviral therapy (1). In prisons in particular,
where there are so many other potential barriers to effective HIV
care, introducing a new and untried technology may seem particularly imprudent to providers.
Since nonadherence is the primary reason for antiretroviral failure
and the development of viral resistance (and cross-resistance) (1) to
the growing, but still limited number of antiretroviral agents, it is
imperative that the effectiveness of new treatment modalities be
questioned. Unfortunately, clinically significant medical outcome
studies on the effectiveness of telemedicine in delivering HIV care
have not been reported. Additional concerns include the rapid
obsolesence of telemedicine equipment, and some providers have
had difficulty furnishing complete paper record copies to telemedicine receiving sites. However, implementation of electronic health
records is on the rise and should circumvent the latter issue. Another
significant factor may be the substantial cost of T-1 lines, even if in
fractional use. Recent dissemination of complementary, lower cost
technologies may decrease telemedicine costs. Some published
reports have demonstrated that telemedicine has reduced correctional health care costs, which is attributed to a reduction in security
and other travel-associated costs incurred when incarcerated
patients are transported from remote sites to specialists (2).
In late 1997, TDCJ Correctional Managed Care developed and
implemented a telemedicine program aimed at providing specialty
care from a site on the The University of Texas Medical Branch at
Galveston (UTMB) campus to patients incarcerated in over 90 prison
units in eastern Texas. For HIV care, as well as other specialty care,
this was a major shift in health care delivery since HIV positive
offenders had always been transported to Hospital Galveston (HG)
for HIV care and participation in clinical trials at UTMB.

Figure1. Clinic Visits
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Despite the fact that a busy eight hour/week telemedicine clinic with
an average census of 35  40 patients per session has been established, an onsite HG HIV Clinic has been maintained to deliver
health care to patients for whom telemedicine has been deemed

Figure 2. Results of Randomly Selected Chart
Review to Internal Audit Purposes

Unincarcerated TDCJ HIV+
HIV+ Patients Patients
Clinic

Community

Telemedicine HG

# appointments
# charts
reviewed
% receiving
ART
% nondetectable VL*

964

1587

1068 296

75

84

72

90 %

83 %

92 % 97 %

49 %

60 %

42 % 76 %

HG
Research

63

*Results compared with one way ANOVA and binomial confidence limits
ART  antiretroviral therapy
VL  virus load (either <50 or < 400 depending on which determination was
most recently performed)
HG = Hospital Galveston
HG Research = Clinial trial study group at HG

inadequate. It is the clinical judgment of the telemedicine provider
to determine whether telemedicine is inadequate. There are no preestablished criteria. The usual reasons for requesting an onsite visit
rather than a telemedicine follow up are that the provider does not
feel that (s)he is "connecting" with the patient, there is a physical
exam finding that cannot be evaluated using telemedicine, or the
patients presentation is too complicated and needs extra attention
in an onsite visit. Failure for a patient to achieve a nondetectable
virus load is not a reason for an onsite visit as long as the provider
feels that (s)he is adequately communicating with the patient and the
patient does not have a physical exam finding that requires a handson exam. Additionally, UTMBs AIDS Care and Clinical Research
Program maintains a clinical trials program for HIV+ prisoners, and
those who wish to be screened and followed on clinical trials must
travel to Galveston for initial screening and study-related follow up.
The introduction of telemedicine provided an opportunity to compare
telemedicine consultation with on-site (HG) consultation in the HIV
care program, and to determine whether HIV care (both telemedicine and HG on-site care) was comparable to local community standards. This study was carried out by conducting a chart review.
As part of the assessment, we asked the question, is there a difference in the proportion of patients with a nondetectable virus load
seen in the community clinic staffed by the same providers who staff
the TDCJ HIV clinics. A random sample of charts of patients seen
between September 2000 and March 2001 was selected from the
Community Clinic (unincarcerated patients), TDCJ Telemedicine
Clinic, TDCJ HG Clinic (TDCJ patients for whom telemedicine has
been deemed inadequate), and TDCJ Research Clinic (HG clinic for
incarcerated patients participating in clinical trials) and were
reviewed for pertinent clinical information including the proportion of
patients receiving antiretroviral treatment and most recent virus load
determination. Since incarcerated patients may attend any of the
three TDCJ clinics depending on clinical circumstances or clinical
trial participation, charts were included for review only if the last
three visits were conducted in the same clinic, or if there were only
two documented visits, both must have occurred in the same clinic
(See Figure 2 above).
Continued on page 6
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Most patients were seen multiple
times during the six-month period
covering this chart review.
Therefore, the approximate number of patients seen in each clinic
can be determined by dividing the
number of appointments by three.
The number of charts reviewed
represents a 15  20% sample of
the total number of patients seen
in each clinic.
A one way analysis of variation
(ANOVA) and binomial confidence
limits analyses were performed
in order to analyze the viral
load response data. The results
showed that a significant difference cannot be detected between
the viral load responses in
Group 1 (Community), Group 2
(Telemedicine), Group 3 (Hospital
Galveston), and Group 4 (HG
Research). Although there was a
trend towards a significant difference in the HG Research Group,
this reached borderline significance in the binomial confidence
limits analysis only. These results
are limited.
This chart review was not a scientifically designed study; it was
done as part of an internal audit
program to determine how to
improve HIV care in the TDCJ.
Patients were not matched for disease stage, sex, race, antiretroviral history, or other factors,
which might influence viral load
response, but the samples were
randomly selected.
The next step is to conduct an
appropriately powered, prospectively-designed trial that considers
variables that determine the overall effectiveness of HIV health care
delivery.
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HEPPigram:

Elevated Liver Function Test

Is the patient on medication that might cause this condition?
i.e., Antiretroviral, TB, and Psych medications

Yes.
Are these medications the likely cause of
the abnormal LFTs?

Yes

No
Refer to
Gastroenterologist or
infectious disease
specialist for evaluation; consider other
viral hepatitides,
nonalcoholic

AST/ALT>4X-5X

Consider stopping
medication

Re-evaluate in
2-3 days

Yet, some preliminary conclusions can be drawn. First, this information agrees with other reports (3, 4) indicating that while approximately 80% of clinical trial participants (HG Research) have a
reduction in virus load to below the levels of detection, the responses in clinical practice are more variable. This finding is expected
since relatively well patients who are less likely to have drugresistant viruses and who have been selected for their ability to
adhere to medical treatment should have the best response to

AST/ALT<4X-5X
Normal
(monitor closely)

Consider other
causes

No.
Consider the causes:
Is there evidence for acute or chronic
viral hepatitis infection determined by the
presence of:
G HCV Ab?
G HAV IgM?
G HBV sAg?

Information
available

Information NOT
available

Screen for
HAV, HBV, HCV

Yes, to one or more.

No

Acute viral hepatitis may require no
treatment or may require symptomatic relief with antiemetics,
intravenous fluids, and other measures. Treatment of chronic active
HBV and HCV and of associated
complications usually requires the
expertise of a gastroenterologist or
infectious disease specialist.

investigational antiretroviral regimens. Second, the viral load
responses of patients seen by ACCRP HIV Specialists are similar
whether the patients are seen by telemedicine or in traditional faceto-face encounters. These preliminary results are very encouraging.
We interpret the results to reflect our experience that telemedicine
can result in the type of patient/provider relationship that translates
into adherence and reduction in viral load to nondetectable levels in
a select group of patients.

References:
1. HIV Treatment Guidelines available at http://www.hivatis.org.
2. Paar, David, Telemedicine in Practice: Texas Department of Criminal Justice, HEPP News, May 2000.
3. S. Guerin, L. Meyer, I. Thodorou, F. Boufassa, M. Magierowska, C. Goujard, C. Rouzioux, P. Debre, J.F. Dlefraissy, and SEROCO/HEMOCO Study Group.
Deletion and Response to HAART in HIV-1-Infected Patients. 7th Conference on Retroviruses and Opportunistic Infections. Abstract # 452, 2000.
4. BY Nguyen, DW Haas, C Ramirez-Ronda, MA Thompson, J Gallant, J Currier, D Paar, C White, A Collier, D Mehrotra, M Chung, C Harvery, J Chodakewitz,
Thirty Two Week Follow-up of Indinavir Sulfate (IDV) Administered Q8 Hours (H) Versus Q12 H in Combination With Zidovudine (ZDV) and Lamivudine (3TC):
The 5th Conference on Retroviruses and Opportunistic Infections. Abstract # 374, 1998.
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Diagnosis of Neoropathy in HIV+ Prison Inmates, A Primer for Correctional Physicians
Contributed by Nicholas J. Capozzoli, MD, DABPN*, Physician and Surgeon in the California Department of Corrections
at the California Medical Center at Vacaville and San Quentin State Prison

Neurologic disease is frequently associated with HIV infection. Both the
central nervous system (CNS) and
the peripheral nervous system (PNS)
may be affected. The causes of neurological disease are various: autoimmune reactions due to immune disregulation; opportunistic infections
(OIs); metabolic and nutritional derangement
due to or associated with AIDS; the direct attack
on nerve tissue by HIV; and the toxic effects of
drugs used to treat HIV and OIs.

Peripheral Neuropathy Treatment
Drug Treatments

Related Comments

G Nortriptyline 10 mg hs: increase dose
by 10mg q 5 days to a maximum of 75
mg hs or 10-20mg po tid
G Neurotin (gabapentin):
300-800 mg po tid
G Ibuprofen 600-800 mg tid
G Topical: Capsaicin-containing ointments
(Zostrix, etc.) For topical application;
Lidocaine ointment 20-30% for topical use
G Alternatives: Phenytoin 200-400mg/d
and crabmazepine 200-400 mg po bid

G Other tricyclics commonly used:
amitriptyline, desipramine, or imipramine
G Capsaicin is often not well tolerated
G Mexiletene: inferior to amitriptyline in
ACTG 242 and appeared no better than a
placebo. Capsaicin ointment treatment disappointing.
G One report of 2 patients suggests
response to HAART (Lancet 1998;
352:1906).
G A controlled trial of acupuncture failed to
show any benefit (JAMA 1998; 280: 1590).
G Nucleosides commonly implicated,

The most common neurologic problem in HIV
infection is peripheral neuropathy (PN), which
involves lesions of the PNS. The major form of
Table adapted from Bartlett JG, and Gallant
PN in HIV disease is distal symmetric polyneuJE. 2000-2001 Medical Management of HIV
ropathy (DSPN), which has been reported to
Infection, p.134.
occur in about a third of patients with AIDS(1).
Several other PN types are associated with HIV
When necessary, the diagnosis of DSPN can be confirmed by elecdisease, mainly acute and chronic inflammatory demyelinating tromyelography (EMG) and nerve conduction velocities (NCVs or
polyradiculoneuropathies (Guillain-Barre-like diseases), mononeuropa- NCSs). My screening protocol for DSPN consists of checking the sural
thy multiplex, and multifocal motor neuropathy. These diseases may sensory, posterior tibial motor, posterior tibial F-waves, and H-reflex
be quite serious and life threatening. It is important to recognize them, waveforms. Needle EMG is performed if there is a suspicion of radicubut they are rare and occur in about 1% of AIDS patients.
lopathy or axonopathy.
DSPN is a "pattern recognition" disease involving a distal and symmetric numbness and/or dysesthesia, the famous "stocking and glove"
distribution. This pattern results from the presumed mechanism of
polyneuropathy, in which there is believed to be a systemic attack upon
the nerves. Nerve repair is under the direction of the nerve cell body,
which contains the nucleus and cell machinery.
In theory, the clinical diagnosis of DSPN is straightforward for any competent examiner. A "directed" neurologic exam for suspected DSPN is
simple and should be performed by the provider when the patients
complaints are consistent with DSPN, i.e., numbness and or pain (usually described as burning, tingling, or "pins and needles") involving the
distal extremities. The toes and feet are usually affected first, and as
the disease progresses the height of the "stocking" will rise. When the
symptoms reach the upper portions of the legs, the fingers and hands
may be affected. There may or may not be weakness of the distal
extremities. DSPN seems to affect primarily sensory nerves, but there
may be some weakness, most often described as "clumsiness."
Patients may complain that they can no longer cross their toes, or that
their fingers are clumsy when they try to perform fine manipulations,
like buttoning a shirt.
The exam consists first of "subjective" sensory testing, where the
examiner uses a safety pin, 128 Hz tuning fork, and cotton swabs to
assess vibration, thermal, light touch, and pain sensation. The tuning
fork is used to evaluate vibration and thermal sensation. In order to test
the latter, the weighted end of the fork is touched to the skin and the
patient is asked whether it feels hot or cold. In DSPN one would expect
the patient to report a distal and symmetric loss of perception of the
various modalities. It is important to check all four modalities.
Next, the "objective" portion of the exam consists of checking the reflex
pattern and muscle bulk and strength. In DSPN, one would expect a
diminution or loss of the ankle jerk reflexes. The most common muscle
bulk abnormality in DSPN is a loss of the extensor digitalis brevis muscles and "high arches" (a pes cavus/talipes deformity), as assessed by
physical inspection. Another objective sign of DSPN is atrophic skin
change, particularly a significant loss of hair from the distal extremities.
Hair is usually present over the great toe and the ankle area.

In my non-prison practice I have found that my clinical diagnosis of
DSPN is supported by EMG/NCS testing 90% of the time. In my prison
practice my clinical diagnosis is supported by the results of EMG/NCS
only 33% of the time. In other words, about 2/3 of my prison patients
who present with "classic" DSPN are normal on all tests.
I have wondered why the clinical impression should be so discordant
with the electrophysiological results in my prison patients. One thing
that impresses me is that there is a higher rate of Hepatitis C coinfection among HIV+ patients in the prison than in the non-prison setting. It
is possible that Hepatitis C coinfection contributes to the symptoms that
mimic DSPN. Chronic hepatitis of all types is associated with pruritis
and burning/tingling dysesthesiae of the extremities. Erythromelalgia is
the specific term for these dysesthesiae. The discomfort of erythromelagia is due to the irritation of dermal nerve endings by circulating
vasoactive substances and toxins, rather than due to actual nerve
damage.
Additionally, one must consider the reality that incarcerated patients
have a high rate of substance dependence and may be influenced by
secondary gain, may be consciously or subconsciously fabricating
and/or amplifying symptoms. A drug addict stuck in prison may be
seeking narcotics or other drugs for purposes other than pain control.
In summary, DSPN is common in patients who have HIV infection. In
the non-prison setting, this diagnosis can usually be confirmed by taking an appropriate history and performing a directed neurological
examination. In correctional medicine, the diagnosis may be complicated by coinfections such as HCV which may cause symptoms that
mimic DSPN and drug-seeking behaviors among a population who
have a high rate of substance dependence. In correctional medicine, if
the diagnosis of DSPN is to be made on purely clinical grounds, it must
be based on objective abnormalities, such as muscle wasting, loss of
deep tendon reflexes, and atrophic skin changes. If these abnormalities are not present, it may be necessary to confirm or exclude the
diagnosis with the use of electrophysiologic testing. A good "screening
protocol" for DSPN includes testing sural sensory, posterior tibial motor
and F-wave studies, and the H-reflexes. If these are completely normal, one can exclude any significant polyneuropathy.

*Nothing to disclose
1. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Arch Neurol. 1988; 45: 945-948.
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Save the
Dates
United States Conference on
AIDS (USCA) 2001
September 13-16, 2001
Fontainebleau Hilton Resort and
Towers/ Miami Beach, Florida
For details, see
http://www.nmac.org/
usca2001/home.htm
Pre-conference symposium on
HIV and Hepatitis in Corrections
sponsored by NMAC and
HEPP News
email: info@nmac.org
call: 202.483.6622
Fee: June 15-August 21:
$375/members;
$450/nonmembers;
On-site: $550
Infectious Disease Society of
America (IDSA): 39th Annual
Meeting
October 2528, 2001
San Francisco, California
Late-breaker abstract deadline:
August 20, 2001
Discounted registration deadline:
July 30, 2001
Write: 99 Canal Center Plaza,
Suite 210 Alexandria, VA 22314
Fax: 703.299.0204
Visit: http://www.idsociety.org

visit HEPP News online at www.hivcorrections.org

News Flashes
Substituting Non-Nucleoside Drugs for
Protease Inhibitors May Result in Lower
Lipid Levels
Protease inihibitors (PIs) have been linked to
certain side effects inlcuding the development
of high levels of lipids (triglycerides and cholesterol) in the blood. Switching patients to a
non-nucleoside based drug regimen (using
Nevirapine or Efavirenz) has been a common
strategy used by physicians to counter this
problem. However, Swiss researchers have
recently found that 38% of patients continued
to have high cholesterol levels once their medication was switched. When the patient was
originally taking the PI Ritonavir, the switch to
Efavirenz was more likely to decrease the
triglyceride levels. Patients originally on other
PIs who switched to Efavirenz had little or no
change in lipid levels. Authors suggest
clinicians should keep this in mind when
considering changes in a patients regimen. In
another study released this week, Viramune
(Nevirapine) did seem to be associated with
lower lipid levels. HIV care providers should be
aware that the "jury is still out" on the effect of
NNRTIs vs PIs on lipid levels. (J AIDS 2001; 26
(4): 389-391.)

United Kingdom are seeing a similar phenomenon, with as many as 25% to 27% of HIV
patients exhibiting resistance to one or more
antiretroviral drugs. The risk of infection by
drug-resistant HIV strains has increased yearly through the 1990s. "Super HAART" regimens, consisting of four or more drugs, is
being used in patients for whom the existing
triple-cocktail therapy has failed. (Reuters,
5/3/01)

HIV Drug Therapies: Failures Reported
Physicians in Pima County, Arizona are beginning to see an increase in AIDS-related deaths
for the first time since the advent of HAART in
1995; the number of AIDS-related deaths this
year is expected to double. Washington State
is also seeing an increase in AIDS cases for
the year 2000, the first increase in nine years.
The percentage of women and minorities with
AIDS is also increasing. These increases may
be attributable to lack of access to treatment
and the beginning of failure of the triple-drug
cocktail which has become the standard regimen for HIV infection. Health officials in the

Mortality Due to End-Stage Liver Disease
Increasing in HIV-Positive Patients
Although HAART has decreased HIV-related
mortality, end-stage liver disease is increasing
in importance as a comorbidity factor. One
study has shown that the percentage of deaths
of HIV-positive patients increased from 11.5%
in 1991 to 50% in 1998-1999. Most of these
patients had detectable antibodies to Hepatitis
C virus (HCV). End-stage liver disease is now
the leading cause of death among HIV-positive
patients in the hospital in where this study was
conducted. (Clinical Infectious Diseases 32 (3):
492, 2/1/01.)

Non-Injection Drug Users at Risk for HCV
Non-injection drug users are at higher risk for
contracting HCV than members of the general
population, according to an National Institutes
of Health release. The findings of a new study
report that 14% of non-injection drug using
women and 17% of non-injection drug using
men tested positive for HCV. This is significantly higher than the 2% prevalence rate of
HCV among members of the general population. Sharing of contaminated syringes in
injection drug use accounts for 60% of HCV
infections. Researchers plan to look further
into the modes of HCV transmission to determine the risks associated with non-injection
drug use. (NIH press release, 5/7/01)

Resources & Websites
Hepatitis Websites:

July 2001 Hepatitis C Virus (HCV) Advocate
http://www.hcvadvocate.org
CDCs Hepatitis webpage
http://www.cdc.gov/ncidod/diseases/hepatitis/index.html
NIHs National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK)
http://www.niddk.nih.gov
The American Liver Foundation
http://www.liverfoundation.org

Medscape HIV/AIDS
http://hiv.medscape.com
Hepatitis C: A Correctional-Public Health Opportunity
http://www.medscape.com/Medscape/ID/journal/2001/v03.n03/mid0
614.groo/mid0614.groo-01.html
HIV Insite:
http://hivinsite.ucsf.edu
AEGiS: The largest HIV/AIDS resource on the Internet
http://www.aegis.com

Neuropathy Websites:

Canadian Hepatitis Info site
http://www.hepnet.com

The Neuropathy Association
http://www.neuropathy.org/index.asp

HIV and Hepatits C Coinfection: ATIS
http://www.hivatis.org/hepatitisC.html

Medicine Net
http://www.medicinenet.com

HIV Treatment Websites:

AIDS Treatment News: Neuropathy
http://www.immunet.org/immunet/atn.nsf/page/a-250-09

HRSA Releases Treatment Guide for Women
http://hab.hrsa.gov/womencare.htm
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through October 31, 2001.
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. What is the first serological marker to appear in acute HBV
infection?
(a) HBc IgG
(b) HBsAb
(c) HBeAg
(d) HBsAg
(e) HbeAb
2. How does prior HIV infection affect the likelihood of
establishing chronic HBV infection?
(a) it has no effect
(b) it increases the chance of establishing chronic
HBV infection
(c) it decreases the likelihood of establishing chronic
HBV infection
(d) it increases the level of HBc IgM in the serum
(e) it decreases serum HBV DNA levels
3. What percentage of new HBV cases develop into chronic
HBV?
(a) 10%
(b) 20%
(c) 25%
(d) 50%
(e) 80%
4. What factors may be responsible for causing abnormal hepatic
transaminase levels?
(a) indinavir
(b) acute or chronic viral hepatitis infection
(c) isoniazid
(d) A and B
(e) A, B, C
5. Which of the following sensations should be tested during the
subjective portion of DSPN diagnosis?
(a) vibration
(b) light touch
(c) pain sensation
(d) thermal sensation
(e) all of the above

HEPP News Evaluation
5 Excellent

4 Very Good

3 Fair

2 Poor

1 Very Poor
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